Drug Trial Radar · NCT03168841
Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients
Last checked: Nov 20, 2026Latest source record: Oct 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jun 6, 2017
Primary completion
Jan 9, 2019
Study completion Jan 9, 2019
Sponsor
- Lead sponsor
- Western University of Health SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Onychomycosis, a common pathology of the toenails, is even more prevalent among diabetic subjects. Nearly 26 million Americans suffer from diabetes, and approximately one-third of subjects with diabetes have toenail onychomycosis. Numerous studies have addressed the efficacy and safety of both topical and oral antifungal treatment options for onychomycosis in diabetic subjects. However, no study to date has specifically addressed the efficacy and safety of efinaconazole among diabetic subjects. The objective of this noncomparative, uncontrolled study is to determine the efficacy of topical efinaconazole 10% for toenail onychomycosis among subjects with diabetes mellitus. Specific indicators to measure efficacy of treatment will be the mycological cure rate, complete cure rate, and treatment success. Furthermore, an additional goal of the study is to gain knowledge of safety in the setting of a cohort of diabetic subjects
Conditions
- Onychomycosis
Interventions
Efinaconazole TopicalDrug
Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Endpoint - EfficacyTime frame: 50 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Western University of Health Sciences
Pomona, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.